6-metabolite blood biomarkers aid differential diagnosis of Parkinson's disease versus healthy controls and other neurodegenerative conditions.

This observational study evaluated the performance of a previously patented 6-metabolite blood biomarker (6M-BB) profiled by 1H NMR for the differential diagnosis of Parkinson's disease (PD). The population included de novo PD patients (n=30), individuals with multiple system atrophy (n=30), progressive supranuclear palsy (n=30), Alzheimer's disease (n=33), and healthy controls (n=29). The setting and publication type were not reported.

The primary outcome was the ability to differentiate PD from other conditions. When comparing PD to healthy controls, the 6M-BB profile demonstrated an area under the curve (AUC) of 0.902, with 87.9% overall accuracy. Sensitivity was 86.7% and specificity was 89.3%. Across all disease groups combined, the overall accuracy was 82.6%. When refitted using an IVDr-based approach, overall accuracy was 77% with an AUC of 0.878.

Incorporating V5FC and citrate significantly improved diagnostic performance. Comparing PD to healthy controls yielded 94.9% accuracy, an AUC of 0.959, sensitivity of 96.7%, and specificity of 93.1%. When comparing PD against MSA, PSP, and healthy controls together, accuracy was 84.9%. Safety data, including adverse events and tolerability, were not reported. No discontinuations occurred.

Key limitations include the need for future prospective multicenter studies to validate these results. The study was externally validated, though funding sources and conflicts of interest were not reported. While the findings support the feasibility and promising potential for clinical implementation, the observational nature of the research prevents causal conclusions. Clinicians should interpret these results as preliminary evidence requiring further confirmation before routine adoption.